APOE4 triples Alzheimer's risk. New study finds the culprit: fat in brain cells

The APOE4 gene variant doesn't just nudge Alzheimer's risk - it can triple it, and in some cases multiply it by 12. Now a team at MIT says it has found the mechanism behind that outsized danger: fat droplets piling up inside the brain's support cells. In a study published Thursday in Cell Stem Cell, Li-Huei Tsai and colleagues show that APOE4 disrupts a key signaling pathway, causing lipids to accumulate and impairing the cells that insulate neurons. The finding could shift how the field thinks about treating the most common form of dementia.

For decades, Alzheimer's research has fixated on two proteins: amyloid-beta and tau. But Tsai, a neuroscientist at MIT, calls lipids the 'third thing that people didn't pay attention to, until recently.' The APOE gene makes proteins that transport fat around cells; the APOE4 version does that job poorly. That inefficiency, the new research suggests, sets off a chain reaction inside oligodendrocytes, the cells that wrap neurons in a fatty insulation called myelin. When myelin production falters, neurons can't signal efficiently - and cognitive decline follows.

APOE4 is the biggest genetic risk factor for late-onset Alzheimer's, the most common form of dementia. Tsai's team has spent about a decade trying to understand how it affects different brain cells. 'APOE4 can influence many different cell types,' she emphasized. 'It's not just one cell type.' Earlier work found cholesterol buildup in astrocytes, star-shaped support cells, and in oligodendrocytes. A drug that helped mice clear that cholesterol improved both myelin production and cognitive performance.

The new study zeroes in on the Wnt signaling pathway, a major communication network between cells. Using stem cells to grow APOE4-carrying oligodendrocytes, the team screened genes that influence fat droplet formation. They found that a gene called DKK1 acts as a brake on Wnt signaling, and that disabling it - lifting the brake - reduced fat droplets. In brain tissue from organ donors with APOE4, the team also saw low Wnt signaling, a clue that the same mechanism operates in humans.

Digging deeper, the researchers traced the disruption to an enzyme whose levels are boosted by APOE4. That enzyme breaks down a protein needed to relay Wnt signals, starving the pathway. In mice, blocking the enzyme restored normal Wnt signaling, cut fat buildup, and helped oligodendrocytes make myelin properly. The treated mice also performed better on cognitive tests, echoing earlier work from the lab.

The implications go beyond a single gene. Rosie Jackson, a cell biologist at the University of Dundee who wasn't involved in the study, said the work 'opens up a new wave of potential therapeutics' that target accumulated fats rather than only amyloid and tau. She expects Alzheimer's treatment to become a cocktail of drugs aimed at different elements of the disease. 'Targeting lipids will be a really important part of that,' she told Live Science.

But the findings haven't been confirmed in humans yet. Co-author Joel Blanchard, a neuroscientist at the Icahn School of Medicine at Mount Sinai, cautioned that the question is how to clear lipids 'in a safe and effective manner in humans.' His own research shows APOE4's reach extends beyond fat: it can scar blood-vessel support cells, contribute to amyloid buildup, and disrupt the 'trash collectors' inside astrocytes. Cells carrying APOE4, he said, put their energy toward fat storage instead of breaking down harmful proteins.

For executives and investors watching the Alzheimer's drug race, the study is a reminder that the next breakthrough may not come from the usual suspects. The global Alzheimer's drug market is already crowded with amyloid-targeting therapies, but lipid metabolism is a fresh angle with mechanistic backing. The challenge now is translating a mouse-tested enzyme blocker into a human-safe drug - a hurdle that has tripped up many promising neuroscience candidates before. If lipid clearance proves viable, it could become a cornerstone of combination therapy - and a new battleground for pharma. For now, the science is early, but the direction is clear: fat metabolism is no longer a side note in Alzheimer's research.